Advertisement
UK markets close in 8 hours 24 minutes
  • FTSE 100

    8,044.81
    0.00 (0.00%)
     
  • FTSE 250

    19,799.72
    0.00 (0.00%)
     
  • AIM

    754.87
    0.00 (0.00%)
     
  • GBP/EUR

    1.1634
    +0.0006 (+0.05%)
     
  • GBP/USD

    1.2441
    -0.0011 (-0.09%)
     
  • Bitcoin GBP

    53,655.60
    +247.53 (+0.46%)
     
  • CMC Crypto 200

    1,416.83
    -7.27 (-0.51%)
     
  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • CRUDE OIL

    83.56
    +0.20 (+0.24%)
     
  • GOLD FUTURES

    2,338.90
    -3.20 (-0.14%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,198.53
    +369.60 (+2.20%)
     
  • DAX

    18,137.65
    +276.85 (+1.55%)
     
  • CAC 40

    8,105.78
    +65.42 (+0.81%)
     

Company News For Jan 30, 2018

Is (TDS) Outperforming Other Utilities Stocks This Year?
  • Lockheed Martin Corporation LMT shares rose 1.9% after reporting fourth-quarter adjusted earnings of $4.30 per share, surpassing the Zacks Consensus Estimate of $4.06

  • Shares of Dr Pepper Snapple Group, Inc. DPS jumped 22.4% after coffee giant Keurig Green Mountain agreed to an $18.7 billion merger deal with Dr Pepper

  • Changyou.com Limited’s CYOU shares slumped 8.9% after reporting fourth-quarter earnings of $0.64 per share, missing the Zacks Consensus Estimate of $0.68

  • Shares of Ablynx NV ABLYF climbed 22.5% after biotech giant Sanofi SNY outbid Novo Nordisk A/S NVO to acquire Ablynx for €3.9 billion or $4.8 billion


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Changyou.com Limited (CYOU) : Free Stock Analysis Report
 
Sanofi (SNY) : Free Stock Analysis Report
 
Novo Nordisk A/S (NVO) : Free Stock Analysis Report
 
Lockheed Martin Corporation (LMT) : Free Stock Analysis Report
 
Dr Pepper Snapple Group, Inc (DPS) : Free Stock Analysis Report
 
ABLYNX NV (ABLYF) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research